$6.99
-0.56-7.42%
Last update: Nov 9, 5:25 PM
AgomAb Therapeutics NV
AGMBNASDAQ
AgomAb Therapeutics fell 48.5% from $14.65 to $7.55, behind the S&P 500's +8.6%. Its worst day was Jun 30 (−27.2%), and its low came Nov 2 at $6.72.
Feb 6, 2026 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-166.72 missed the $-1.79 estimate on $0.00 revenue.
+3.3% · S&P 500 +0.8%
AgomAb Therapeutics shares fell 16.6%, while the S&P 500 fell 2.6%.
−16.6% · S&P 500 −2.6%
Story events cover the past 12 months · Times ET
AgomAb Therapeutics closed at its highest level of the year, 21.6% above where the year started.
+29.0%, the year's best day · S&P 500 +1.6%
EPS of $-0.93 was reported on $0.00 revenue.
+7.4% · S&P 500 +0.6%
Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating
−22.1% · S&P 500 +0.2%
AgomAb Therapeutics closed at its lowest level of the year, 54.1% below where the year started.
−10.3% · S&P 500 −0.5%
Where it ended: a close of $7.55 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.32).
Nothing in the past 12 months.
All AGMB dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AGMB and SPY from Benzinga historical bars. Not investment advice.
